The incidence of total shoulder arthroplasty (TSA) and reverse shoulder arthroplasty (RTSA) continues to rapidly increase in the United States, with a documented 5-fold rise over the previous decade.[@bib36] A growing proportion of these procedures are RTSA, with one recent study finding RTSA accounting for 33% of all shoulder arthroplasty, along with 44% TSA and 23% hemiarthroplasty (HA).[@bib29] The implant designs have also undergone rapid changes with the advent of short stems and now most recently stemless components.

Theoretical advantages of stemless designs include preservation of humeral bone stock, reduced periprosthetic fracture with the elimination of broaching, reduction in stress shielding, more flexibility in reconstruction in cases of altered anatomy such as post-traumatic malunion, and less complex revision surgery.[@bib10], [@bib11], [@bib16] The numerous potential benefits make these new implants a promising option in the near future for clinical practice.

However, there are also possible disadvantages including the theoretical risk of component loosening before osseous ingrowth has occurred and the reliance on adequate humeral metaphyseal bone stock. Although in some cases lesser tuberosity fixation after osteotomy may be more challenging with stemless designs, there are several modern strategies to obtain a robust subscapularis repair including suture anchors, transosseous tunnels, and direct tendon to tendon repair. Although the lack of long-term follow-up (FU) has made some surgeons hesitant to use these implants, since the introduction of the stemless design in Europe in 2004, there have now been a growing number of studies reporting on medium-term 5- to 10-year FU.[@bib15], [@bib17], [@bib37]

With several smaller studies present in the literature, a larger comprehensive analysis of the data available for stemless shoulder analysis can be performed. We present a systematic review of the published studies of patients undergoing stemless TSA, HA, and RTSA. Attention is focused on functional outcomes as well as reported complication and revision rates. We hypothesized that functional outcomes would be similar for stemless versus stemmed implants, and that humeral complications would not differ substantially from previously published rates for stemmed components.

Methods {#sec1}
=======

A broad search of English-language literature was conducted beginning from January 1, 2000, through August 1, 2018. Investigators searched both MEDLINE through PubMed and Google Scholar using MeSH search terms including "stemless," "canal-sparing," "reverse," "shoulder replacement," or "shoulder arthroplasty." A manual reference check of previous reviews and published studies was conducted to identify any additional relevant studies.

To meet inclusion criteria, studies needed to include more than 5 patients undergoing TSA, HA, or RTSA report functional outcomes measured using either standardized metrics or range of motion (ROM) measurement, and explicitly comment on complications. No threshold was set for minimum FU time. Studies were classified according to the mean length of FU into 3 groups: very short term (mean FU \<18 months), short term (FU 18-60 months), and medium term (60-120 months).

Outcome measures reported by the authors varied substantially. Most included Constant-Murley scores (CMS),[@bib12] with other common metrics including the Disabilities of the Arm, Shoulder, and Hand score and the American Shoulder and Elbow Surgeons score. Most authors also reported explicit measures of ROM, such as external rotation (ER), abduction, and flexion.

All complications were examined in each study, with attention focused on humeral component--related complications and revisions. Revision rates due to failure of the humeral or glenoid component were also summarized. Study, patient, and treatment characteristics were summarized with the use of basic descriptive statistics.

Results {#sec2}
=======

A total of 19 studies of anatomic stemless TSA and HA were included in the analysis, with a mean FU between 6 and 108 months. Across the 19 included studies, a total of 1115 patients who underwent stemless TSA (n = 814) or HA (n = 301) were identified: 212 in very short--term FU studies, 741 in short-term FU studies, and 162 in medium-term FU studies ([Table I](#tbl1){ref-type="table"}). A total of 6 studies involving stemless RTSA were identified involving 346 patients, all with a mean FU in the short-term category between 18 and 60 months ([Table IV](#tbl4){ref-type="table"}).Table ISummary of stemless anatomical TSA and HA studies identified, grouped by average length of follow-upStudyDeviceTypePatientsReported indicationsMean FU (mo)Reported outcomesTSAHAMedium term Habermeyer et al 2015[@bib15]Arthrex/EclipseCase series2939Primary OA, post-trauma OA, postinfectious OA, instability, CTA, GD72CMS, ER, Flex, Abd Hawi et al 2017[@bib17]Arthrex/EclipseCase series1732Post-trauma OA, primary OA, instability, CTA, postinfectious OA108CMS, ER, Flex, Abd Uschok et al 2017[@bib37]Arthrex/EclipseRandomized14Primary OA68CMS, ER, Flex, Abd Beck et al 2018[@bib4]Biomet/TESSCase series31Primary OA, RA, post-traumatic and HH necrosis95CMS, QuickDASH, VAS, Abd, FlexShort term Huguet et al 2010[@bib19]Biomet/TESSCase series1944Primary OA, post-trauma OA, osteonecrosis45CMS, ER, Flex Brunner et al 2012[@bib8]Arthrex/EclipseCase series119114Primary OA, post-trauma OA, postinfectious OA, AVN, RA, instability, CTA23CMS, ER, Flex, Abd Berth and Pap 2012[@bib6]Biomet/TESSRandomized41Primary OA31CMS, DASH, ER, Abd, Flex Razmjou et al 2013[@bib27]Biomet/TESSComparative17Primary OA\>24RCMS, ASES, QuickDASH, WOOS Bell and Coghlan 2014[@bib5]Mathys/AffinisCase series12Primary OA\>24CMS, ASES, DASH, SPADI, Abd Mariotti et al 2014[@bib25]Wright Med/SimplicitiComparative9Primary OA24CMS, SST, ER, IR, Abd, Flex Ballas et al 2016[@bib3]Biomet/TESSCase series27Malunion44CMS Churchill et al 2016[@bib11]Wright Med/SimplicitiCase series149Primary OA, post-trauma OA\>24CMS, ASES, SST, VAS, ER, Abd, IR Spranz et al 2017[@bib33]Biomet/TESSComparative12Primary OA52CMS, ER, Flex, Ext, Abd Krukenberg et al 2018[@bib22]Zimmer/SidusCase series7332Primary OA, post-trauma OA, AVN, instability, RA\>24CMS, ASES, SSV, ER, Flex Heuberer et al 2018[@bib18]Arthrex/EclipseCase series3340Primary OA, post-trauma OA58CMSVery short term Sayed-Noor et al 2018[@bib28]Biomet/TESSCase series63Primary OA12QuickDASH, ER, Abd Maier 2015[@bib24]Biomet/TESSComparative12Primary OA6CMS, ER, IR, Abd, Flex Schoch et al 2011[@bib30]Arthrex/EclipseCase series115Primary OA, post-trauma OA12CMS, ER, Abd, Flex Kadum et al 2011[@bib20]Biomet/TESSCase series22Primary OA, post-trauma OA, RA14QuickDASH, EQ-5D, VAS[^1]Table IISummary of humeral component complications in stemless anatomical TSA and HAStudyPatientsComplicationsRadiologic changesRelated revisionsMedium term Habermeyer et al 2015[@bib15]781 incomplete RLL, 3 partial osteolysis under HH, 34% with decreased BD of GTNone Hawi et al 2017[@bib17]431 asymptomatic radiological loosening1 incomplete RLL on HH, 29% decrease BD over GTNone Uschok et al 2017[@bib37]14Reduced BD in GT in 29%None Beck et al 2018[@bib4]31NoneNoneShort term Huguet et al 2010[@bib19]635 intraoperative fracture of metaphysisNone Brunner et al 2012[@bib8]2331 asymptomatic radiological loosening9 incomplete RLL \<2 mm, 5 incomplete RLL \>2 mm, 2 RLL \>2 mmNone Berth and Pap 2012[@bib6]41NoneNone Razmjou et al 2013[@bib27]171 RLL Bell and Coghlan 2014[@bib5]12NoneNone Mariotti et al 2014[@bib25]9None Ballas et al 2016[@bib3]271 osteolysis under HHNone Churchill et al 2016[@bib11]149NoneNone Spranz et al 2017[@bib33]12 Krukenberg et al 2018[@bib22]1051 intraoperative fracture greater tuberosity1 incomplete RLL HHNone Heuberer et al 2018[@bib18]738 with signs osteolysis, decreased BD over GT in 43%NoneVery short term Sayed-Noor et al 2018[@bib28]63None Maier 2015[@bib24]12None Schoch et al 2011[@bib30]115 Kadum et al 2011[@bib20]22[^2]Table IIISummary of glenoid component complications in stemless anatomical TSA and HAStudyPatientsComplicationsRadiologic changesRelated revisionsMedium term Habermeyer et al 2015[@bib15]782 looseningIncomplete RLL in 8.3% of MBC and 53% of cemented2 Hawi et al 2017[@bib17]435 with RLL, 27% with incomplete RLLNone Uschok et al 2017[@bib37]142 loosening2 incomplete RLL0 Beck et al 2018[@bib4]311 loosening, 1 failure MBC20 of 22 with RL1Short term Huguet et al 2010[@bib19]63None Brunner et al 2012[@bib8]2331 looseningNone1 Berth and Pap 2012[@bib6]411 intraoperative fracture9 with RLNone Razmjou et al 2013[@bib37]176 intraoperative perforation1 subsidence Bell and Coghlan 2014[@bib5]128 incomplete RLLNone Mariotti et al 2014[@bib25]9None Ballas et al 2016[@bib3]27NoneNone Churchill et al 2016[@bib11]1491 looseningNone1 Spranz et al 2017[@bib33]12NR Krukenberg et al 2018[@bib22]1056 complete RLL, 10 incomplete RLLNone Heuberer et al 2018[@bib18]73NoneNoneVery short term Sayed-Noor et al 2018[@bib28]63NRNone Maier 2015[@bib24]12NRNone Schoch et al 2011[@bib30]1152 looseningNR Kadum et al 2011[@bib20]22NR[^3]Table IVSummary of stemless RTSA studies identifiedStudyDeviceTypePatientsReported indicationsMean FU (mo)Reported outcomesBallas and Béguin 2013[@bib2]Biomet/TESSCase series56RCT, CTA, primary OA59CMS, OSS, ER, AbdKadum et al 2014[@bib21]Biomet/TESSComparative16CTA, primary OA with RCD, post-trauma sequelae, RA39QuickDASH, EQ-5D, VAS, IR, Abd, FlexTeissier et al 2015[@bib34]Biomet/TESSCase series87RCT, CTA41CMS, QuickDASH, ASES, ER, Abd, Flexvon Engelhardt et al 2015[@bib38]Biomet/TESSCase series65CTA, revision arthroplasty18RCMS, DASHLevy et al 2016[@bib23]IDO/VersoCase series98CTA, post-trauma sequelae, RA, RCT, RCD50CMS, SSV, ER, IR, AbdMoroder et al 2016[@bib26]Biomet/TESSComparative24CTA34CMS, ASES, SSV, VAS[∗](#tbl4fnlowast){ref-type="table-fn"}[^4][^5]

A total of 5 stemless TSA/HA implants from 6 different prosthesis companies were identified. These included the Total Evolutive Shoulder System (TESS; Biomet, Warsaw, IN, USA), the Eclipse stemless shoulder prosthesis (Arthrex, Freiham, Germany) ([Fig. 1](#fig1){ref-type="fig"}, *A, B*), the Affinis (Mathys AG, Bettlach, Switzerland), the Sidus Stem-Free Shoulder System (Zimmer Biomet, Warsaw, IN, USA), and the Simpliciti total shoulder system (Wright Medical, Memphis, TN, USA) ([Fig. 1](#fig1){ref-type="fig"}, *C, D*). The Simpliciti by Wright Medical and the Sidus system by Zimmer Biomet are the only devices currently Food and Drug Administration approved for use in the United States.Figure 1Humeral components from 2 stemless total shoulder arthroplasty systems most commonly found in literature. (**A**) Picture of the Eclipse (Arthrex, Naples, FL, USA) from Habermeyer et al,[@bib15] with (**B**) the representative AP radiograph from Brunner et al.[@bib8] (**C**) Picture of Simpliciti (Wright Medical, Memphis, TN, USA) and (**D**) the representative anteroposterior radiography both from Churchill et al.[@bib11]

A total of 2 stemless RTSA implants were identified including the TESS short reverse corolla (Biomet) and the Verso stemless reverse metaphyseal TSA prosthesis (Innovative Design Orthopaedics, London, UK). Neither stemless RTSA device is currently approved by the Food and Drug Administration.

Stemless TSA and HA outcomes {#sec2.1}
----------------------------

Primary osteoarthritis was the most common indication reported for stemless TSA, though studies varied in the indications included in analysis. There was considerable variability in reported outcome measures; the most commonly reported is the CMS with 84% (n = 16) of studies reporting preoperative and postoperative values ([Table I](#tbl1){ref-type="table"}). A total of 73% (n = 14) of studies were case series, 15% (n = 3) of studies were nonrandomized comparisons of stemmed and stemless humeral components, and 10% (n = 2) were randomized studies of stemmed versus stemless components.

Looking specifically at the randomized trials, the study by Berth and Pap[@bib6] analyzed 82 patients evenly randomized to stemless (TESS; Biomet) or cemented stem components. They found no difference in functional outcomes at more than 24 months of FU; however, there was significantly increased operating room (OR) time (106 vs. 92 minutes) and estimated blood loss (593 vs. 496 mL) reported in the stemmed group compared with the stemless group. The second study by Uschok et al[@bib37] analyzed 40 patients randomized to stemless (Eclipse; Arthrex) or press-fit stem components, with 29 patients available for analysis at more than 60 months of FU. The authors found no difference in functional outcomes between either group postoperatively.

A graphical representation of 2 commonly reported outcomes, ER and CMS, is displayed in [Figure 2](#fig2){ref-type="fig"}. Across studies, there was a reliable improvement in both CMS and ER postoperatively compared with preoperatively, with a roughly 30-point improvement in CMS and a 20° increase in ER.Figure 2Reported outcomes before and after anatomical stemless total shoulder arthroplasty and hemiarthroplasty for Constant-Murray score (**A**) and external rotation (**B**). Colors represent each study, with warm colors corresponding to medium-term follow-up studies and cool colors corresponding to short-term follow-up studies. Very short--term studies (average follow-up \<18 months) were excluded.

Stemless RTSA outcomes {#sec2.2}
----------------------

The most common indications were cuff tear arthropathy and rotator cuff tear ([Table IV](#tbl4){ref-type="table"}). Four studies were case series reporting a variety of outcomes. Two studies were nonrandomized comparisons between stemmed and stemless RTSA components, neither finding any significant difference in functional outcomes.

Reported outcomes varied substantially between studies, with 50% (n = 3) of the studies reporting CMS preoperatively and postoperatively, 1 reporting only postoperative values, and the remaining 2 studies using other outcome measures including the Disabilities of the Arm, Shoulder, and Hand score.

CMS and ER and abduction measurements preoperatively and postoperatively are summarized in [Figure 3](#fig3){ref-type="fig"} for those studies with the available information. There was an approximately 30-point improvement in CMS, a 20° increase in ER, and a 60° increase in abduction ([Figure 3](#fig3){ref-type="fig"}).Figure 3Reported outcomes before and after stemless reverse total shoulder arthroplasty for Constant-Murray score (**A**), external rotation (**B**), and abduction (**C**). Colors represent each study. The size of the point represents the number of patients in each study.

Complications {#sec2.3}
-------------

Of the 1115 stemless TSA and HA patients included, 0.7% (n = 8) of complications were related to the humeral component ([Table II](#tbl2){ref-type="table"}). Six were intraoperative fracture,[@bib19], [@bib22] 5 of which were reported in the first published study on stemless components, and all healed with nonoperative management. Two complications were asymptomatic loosening confirmed by radiology.[@bib17], [@bib8] There were no revisions related to the humeral component. Four studies also reported changes in bone density over the greater tuberosity, with higher percentages indicating greater internal stress shielding, present in 29%,[@bib37] 29%,[@bib17] 34%,[@bib15] and 43%[@bib18] of patients undergoing stemless TSA. The one comparative study reporting changes in greater tuberosity bone density found a higher rate of reduced bone density in stemmed (47%) compared with stemless TSA components (29%), though this difference was not significant and the clinical relevance is not clear (*P* = .4).[@bib37] When comparing bone density at the humeral calcar however, a significant increase in the rate of reduced bone density was found in the stemmed group (41%) compared with the stemless group (0%).[@bib37]

Of the 346 stemless RTSA patients included, 1.7% (n = 6) experienced complications related to the humeral component ([Table V](#tbl5){ref-type="table"}). Two of 6 were instances of symptomatic loosening,[@bib2], [@bib38] of which all were revised to a stemmed humeral component (one after 3 days, the other not reported). Three complications were intraoperative fracture of the metaphysis, all managed conservatively.[@bib2], [@bib23] One case involved malpositioning of the humeral component, which required revision to a stemmed humeral component in the immediate postop period.[@bib38] Radiographical changes were sparingly reported with only 3 reports of incomplete radiolucent lines surrounding the humeral component.[@bib26]Table VSummary of humeral component complications in stemless RTSAStudyPatientsComplicationsRadiologic changesRelated revisionsBallas and Béguin 2013[@bib2]561 intraoperative fracture of metaphysis, 1 loosening (3 d)None1Kadum et al 2014[@bib21]16NoneNoneNoneTeissier et al 2015[@bib34]87NoneNoneNonevon Engelhardt et al 2015[@bib38]671 loosening (in revision), 1 malpositionNR2Levy et al 2016[@bib23]982 intraoperative fracture of metaphysisNoneNoneMoroder et al 2016[@bib26]24None3 incomplete RLLNone[^6]

There were substantially more complications related to the glenoid component in patients undergoing TSA and RTSA. Of the 814 anatomic TSA patients, 2.1% (n = 17) experienced complications involving the glenoid component: 9 patients with loosening, 7 with intraoperative fracture or perforation, and 1 failure of the metal-backed component ([Table III](#tbl3){ref-type="table"}). A total of 29% (n = 5) of these patients required revision of the glenoid component. Of the 346 RTSA stemless RTSA patients, 3.2% (n = 11) experienced complications involving the glenoid component: 9 patients with loosening and 2 with malpositioning ([Table VI](#tbl6){ref-type="table"}). A total of 90% (n = 10) of these patients required revision of the glenoid component.Table VISummary of glenoid component complications in stemless RTSAStudyPatientsComplicationsRadiologic changesScapular notching (%)Related revisionsBallas and Béguin 2013[@bib2]563 disassociationNone5 (9)3Kadum et al 2014[@bib21]162 looseningNone4 (25)2Teissier et al 2015[@bib34]87NoneNone17 (19)Nonevon Engelhardt et al 2015[@bib38]673 loosening, 2 malpositioningNR9 (13)4Levy et al 2016[@bib23]981 looseningNone21 (22)1Moroder et al 2016[@bib26]24NoneNR2 (8)None[^7]

Discussion {#sec3}
==========

The body of literature regarding stemless anatomic and RTSA continues to grow with the available prospective and randomized studies showing outcomes similar to traditional stemmed counterparts. Across retrospective case series, there were consistent improvements in commonly reported outcomes including functional scores and ROM measurements. In the available comparative studies, there was also no difference in functional outcomes between stemmed and stemless components. These outcomes are maintained in the medium-term studies identified for anatomic TSA, with a mean FU more than 60 months. Standardization across reported outcomes, including both preoperative and postoperative values, would enable more robust meta-analyses in the future.

Data from 2 studies supported claims that stemless shoulder replacement results in shorter operative time compared with stemmed components. The aforementioned randomized study by Berth and Pap[@bib6] found a decreased OR time of roughly 15 minutes and a decreased estimated blood loss of roughly 100 mL in the stemless group compared with the stemmed group. Heuberer et al[@bib18] found operative time to be more than 20 minutes shorter in both stemless TSA and HA compared with stemmed alternatives (*P* \< .001). This is an important benefit as shorter OR times have been shown to result in fewer postoperative infections, reduced complications, and decreased cost.[@bib9], [@bib13], [@bib39]

Regarding other advantages and disadvantages, previous literature has highlighted the concern for increased loosening of stemless components, while citing decreased intraoperative fracture as a theoretical benefit. This review found a 0.2% rate of asymptomatic humeral loosening (none of which required revision) and a 0.5% rate of intraoperative humeral fracture in patients undergoing stemless TSA or HA. The most recent systematic review of complication rates in anatomic and reverse stemmed shoulder arthroplasty found a 0.1% rate of humeral loosening and a 0.6% rate of intraoperative humeral fracture,[@bib7] with an intraoperative fracture rate as high as 1.5% in other studies.[@bib1] Thus, in studies we identified, outcomes for anatomic stemless designs were found to have a comparable rate of humeral component loosening and similar if not slightly less rate of intraoperative fracture compared with stemmed components.

In cases of stemmed RTSA, reported rates of humeral loosening are 0.7%, and although isolated humeral fracture rates are not clearly available, 2.3% of RTSA were complicated by either a glenoid or humerus intraoperative fracture.[@bib7] In this review, the 6 studies available for stemless RTSA demonstrated a 0.6% rate of humeral component loosening and a 0.9% rate of humeral intraoperative fracture with no instances of glenoid fracture. Although our identified rate of humeral loosening for stemless RTSA was slightly higher than the rate identified in a recent systemic review of stemmed components,[@bib7] we cannot comment on the significance of this difference given the small number of stemless RTSA patients available in the literature.

In the studies identified, we found reliable improvements in functional outcomes and largely equivocal complication rates for stemless anatomic TSA, HA, and RTSA compared with those published for stemmed components. However, there are multiple limitations to the current body of literature. First, there is an absence of long-term FU studies with an average FU of 10 years or more for stemless implants. For stemmed TSA and HA components, multiple studies have examined patients at 15 and 20 years of FU, finding survival rates of 87% to 88% at 15 years and 84% to 85% at 20 years.[@bib14], [@bib31], [@bib32], [@bib35] Survival is substantially lower for stemmed anatomic HA averaging 75% to 76% at 20 years.[@bib31], [@bib32] Second, there is a relative lack of randomized studies comparing stemmed and stemless components. Although these studies may be expensive, reliance on data from case reports introduces the possibility of selection bias, which may result in underestimates of complication and revision rates associated with these new prostheses. Finally, one of the main theoretical advantages of stemless components is the preservation of bone stock and subsequently less complicated secondary or revision surgery. Although there is little data on the available literature on revisions of stemless humeral components (possibly because of their current lack of long-term FU), a study comparing outcomes in revision of stemless versus stemmed implants could shed new light on this possible advantage.

Conclusion {#sec4}
==========

In our review of all the current available literature, we identified a total of 25 studies with 1461 patients who underwent stemless TSA, HA, or RTSA. Two randomized studies were available that showed no difference in functional outcomes between patients who received stemless or stemmed components. In the studies that reported similar outcome measures, there were reliable improvements in CMS and ROM including ER and abduction. Aggregate complication rates appear similar to those reported in the literature for stemmed implants. Overall, the current data on stemless implants are promising; however, evidence supporting the utility and safety of these relatively new designs would be strengthened by longer-term FU and additional randomized studies.

Disclaimer {#sec5}
==========
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[^1]: *TSA*, total shoulder arthroplasty; *HA*, hemiarthroplasty; *FU*, follow-up; *OA*, osteoarthritis; *CTA*, cuff tear arthropathy; *GD*, glenoid dysplasia; *CMS*, Constant-Murley score; *ER*, external rotation; *Flex*, flexion; *Abd*, Abduction; *TESS*, Total Evolutive Shoulder System; *RA*, rheumatoid arthritis; *HH*, humeral head; *DASH*, Disabilities of the Arm, Shoulder, and Hand score; *VAS*, visual analog scale for pain; *AVN*, avascular necrosis; *RCMS*, relative Constant-Murley score; *ASES*, American Shoulder and Elbow Surgeons score; *WOOS*, Western Ontario Osteoarthritis Shoulder score; *SPADI*, Shoulder Pain and Disability Index; *SST*, Simple Shoulder Test; *IR*, internal rotation; *SSV*, Subjective Shoulder Value.

[^2]: *TSA*, total shoulder arthroplasty; *HA*, hemiarthroplasty; *RLL*, radiolucent lines; *HH*, humeral head; *BD*, bone density; *GT*, greater tuberosity.

[^3]: *TSA*, total shoulder arthroplasty; *HA*, hemiarthroplasty; *RLL*, radiolucent lines; *MBC*, metal-backed component; *RL*, radiolucent; *NR*, not reported.

[^4]: *RTSA*, reverse total shoulder arthroplasty; *FU*, follow-up; *TESS*, Total Evolutive Shoulder System; *RCT*, rotator cuff tear; *CTA*, cuff tear arthropathy; *OA*, osteoarthritis; *CMS*, Constant-Murley score; *OSS*, Oxford Shoulder Score; *ER*, external rotation; *Abd*, abduction; *RCD*, rotator cuff deficiency; *RA*, rheumatoid arthritis; *DASH*, Disabilities of the Arm, Shoulder, and Hand score; *VAS*, visual analog scale; *IR*, internal rotation; *Flex*, flexion; *ASES*, American Shoulder and Elbow Surgeons score; *RCMS*, relative Constant-Murley score; *SSV*, Subjective Shoulder Value.

[^5]: Only postoperative values reported for these scores.

[^6]: *RTSA*, reverse total shoulder arthroplasty*; NR*, not reported; *RLL*, radiolucent lines.

[^7]: *RTSA*, reverse total shoulder arthroplasty; *NR*, not reported.
